Skip to main content

Table 3 Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 61 triple-negative and 45 HER2-positive breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters

PD-1

PD-L1

PD-L2

Positive (n = 18)

Negative (n = 43)

p value

Positive (n = 24)

Negative (n = 37)

p value

Positive (n = 20)

Negative (n = 41)

p value

TNBC (n = 61)

 Age at operation

  ≤ 56

4 (22.2%)

24 (55.8%)

0.016

10 (41.7%)

18 (48.6%)

0.593

12 (60.0%)

16 (39.0%)

0.123

  > 56

14 (77.8%)

19 (44.2%)

14 (58.3%)

19 (51.4%)

8 (40.0%)

25 (61.0%)

 Menopause

  Negative

4 (22.2%)

18 (41.9%)

0.121

9 (37.5%)

13 (35.1%)

0.851

8 (40.0%)

14 (34.1%)

0.655

  Positive

14 (77.8%)

25 (58.1%)

15 (62.5%)

24 (64.9%)

12 (60.0%)

27 (65.9%)

 Tumor size (cm)

  ≤ 2

3 (16.7%)

4 (9.3%)

0.337

3 (12.5%)

4 (10.8%)

0.573

3 (15.0%)

4 (9.8%)

0.416

  > 2

15 (83.3%)

39 (90.7%)

21 (87.5%)

33 (89.2%)

17 (85.0%)

37 (90.2%)

 Lymph node status

  Negative

3 (16.7%)

8 (18.6%)

0.586

5 (20.8%)

6 (16.2%)

0.647

3 (15.0%)

8 (19.5%)

0.481

  Positive

15 (83.3%)

35 (81.4%)

19 (79.2%)

31 (83.8%)

17 (85.0%)

33 (80.5%)

 Nuclear grade

  1, 2

13 (72.2%)

31 (72.1%)

0.992

19 (79.2%)

25 (67.6%)

0.324

14 (70.0%)

30 (73.2%)

0.795

  3

5 (27.8%)

12 (27.9%)

5 (20.8%)

12 (32.4%)

6 (30.0%)

11 (26.8%)

 Ki67

  ≤ 14%

6 (33.3%)

12 (27.9%)

0.672

12 (50.0%)

6 (16.2%)

0.005

6 (30.0%)

12 (29.3%)

0.953

  > 14%

12 (66.7%)

31 (72.1%)

12 (50.0%)

31 (83.8%)

14 (70.0%)

29 (70.7%)

 Pathological response

  pCR

3 (16.7%)

25 (58.1%)

0.003

3 (12.5%)

25 (67.6%)

< 0.001

10 (50.0%)

18 (43.9%)

0.654

  Non-pCR

15 (83.3%)

18 (41.9%)

21 (87.5%)

12 (32.4%)

10 (50.0%)

23 (56.1%)

 PD-1

  Negative

Not determined

Not determined

 

9 (37.5%)

34 (91.9%)

< 0.001

12 (60.0%)

31 (75.6%)

0.210

  Positive

15 (62.5%)

3 (8.1%)

8 (40.0%)

10 (24.4%)

 PD-L1

  Negative

3 (16.7%)

34 (48.4%)

< 0.001

Not determined

Not determined

 

10 (50.0%)

27 (65.9%)

0.234

  Positive

15 (83.3%)

9 (51.6%)

 

10 (50.0%)

14 (34.1%)

 PD-L2

  Negative

10 (55.6%)

31 (79.1%)

0.210

14 (58.3%)

27 (73.0%)

0.234

Not determined

Not determined

 

  Positive

8 (44.4%)

12 (20.9%)

10 (41.7%)

10 (27.0%)

Parameters

PD-1

PD-L1

PD-L2

Positive (n = 3)

Negative (n = 42)

p value

Positive (n = 4)

Negative (n = 41)

p value

Positive (n = 16)

Negative (n = 29)

p value

HER2+BC (n = 45)

 Age at operation

  ≤ 56

0 (0.0%)

20 (47.6%)

0.162

1 (25.0%)

19 (46.3%)

0.394

6 (37.5%)

14 (48.3%)

0.486

  > 56

3 (100.0%)

22 (52.4%)

3 (75.0%)

22 (53.7%)

10 (62.5%)

15 (51.7%)

 Menopause

  Negative

0 (0.0%)

18 (42.9%)

0.206

1 (25.0%)

17 (41.5%)

0.471

6 (37.5%)

12 (41.4%)

0.799

  Positive

3 (100.0%)

24 (57.1%)

3 (75.0%)

24 (58.5%)

10 (62.5%)

17 (58.6%)

 Tumor size (cm)

  ≤ 2

1 (33.3%)

5 (11.9%)

0.356

1 (25.0%)

5 (12.2%)

0.448

4 (25.0%)

2 (6.9%)

0.107

  > 2

2 (66.7%)

37 (88.1%)

3 (75.0%)

36 (87.8%)

12 (75.0%)

27 (93.1%)

 Lymph node status

  Negative

1 (33.3%)

15 (35.7%)

0.715

2 (50.0%)

14 (34.2%)

0.448

5 (31.3%)

11 (37.9%)

0.455

  Positive

2 (66.7%)

27 (64.3%)

2 (50.0%)

27 (65.8%)

11 (68.7%)

18 (62.1%)

 Nuclear grade

  1, 2

2 (66.7%)

33 (78.6%)

0.539

2 (50.0%)

33 (80.5%)

0.209

12 (75.0%)

23 (79.3%)

0.508

  3

1 (33.3%)

9 (21.4%)

2 (50.0%)

8 (19.5%)

4 (25.0%)

6 (20.7%)

 Ki67

  ≤ 14%

1 (33.3%)

23 (54.8%)

0.449

1 (25.0%)

23 (56.1%)

0.254

7 (43.8%)

17 (58.6%)

0.338

  > 14%

2 (66.7%)

19 (45.2%)

3 (75.0%)

18 (43.9%)

9 (56.2%)

12 (41.4%)

 Pathological response

  pCR

0 (0.0%)

18 (42.9%)

0.206

1 (25.0%)

17 (41.5%)

0.471

11 (62.5%)

7 (24.1%)

0.005

  Non-pCR

3 (100.0%)

24 (57.1%)

3 (75.0%)

24 (58.5%)

5 (37.5%)

22 (75.9%)

 PD-1

  Negative

Not determined

Not determined

 

1 (25.0%)

41 (100.0%)

< 0.001

13 (81.3%)

29 (100.0%)

0.039

  Positive

3 (75.0%)

0 (0.0%)

3 (18.7%)

0 (0.0%)

 PD-L1

  Negative

0 (0.0%)

41 (97.6%)

< 0.001

Not determined

Not determined

 

12 (75.0%)

29 (100.0%)

0.012

  Positive

3 (100.0%)

1 (2.4%)

4 (25.0%)

0 (0.0%)

 PD-L2

  Negative

0 (0.0%)

29 (69.0%)

0.039

0 (0.0%)

29 (70.7%)

0.012

Not determined

Not determined

 

  Positive

3 (100.0%)

13 (31.0%)

4 (100.0%)

12 (29.3%)

  1. TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand